8-K - Amphastar Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Amphastar Pharmaceuticals, Inc. disclosed two related party agreements effective March 3, 2026: a 5-year Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. for chemical intermediates via its subsidiary Amphastar Nanjing Pharmaceuticals, Inc., and an amendment to a Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. changing product candidate from AMP-107 to AMP-105 and increasing total cost by approximately $0.6 million. Both were approved by the Audit Committee and deemed non-material to financial condition or results of operations.

Key Takeaways

1Supply Agreement effective March 3, 2026 between Amphastar Nanjing Pharmaceuticals, Inc. and Nanjing Letop Biotechnology Co., Ltd. for chemical intermediates, 5-year term, payments in Chinese yuan.

2No minimum purchase obligation under Supply Agreement.

3Contract Research Amendment effective March 3, 2026 changes product to AMP-105 from AMP-107, adds ~$0.6 million cost.

4Letop majority owned by Henry Zhang, immediate family member of CEO Dr. Jack Zhang and Chairman Dr. Mary Luo.

5Hanxin majority owned by Dr. Jack Zhang, Dr. Mary Luo, and family; Henry Zhang is general manager and chairman.

6Both transactions approved by Audit Committee; company states neither is material.

Current Report Details

Event Type

Material Agreement

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement. Supply Agreement. On March 3, 2026, (the “Effective Date”), Amp

Material Agreement

9.01

. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1* Supply Agreement by and between Amphastar Nanjing Pharmaceuticals, Inc. and N

Exhibits Only

Transaction Details

Material Agreement

Exhibits (3)

10.1

EX-10.1

10.2

EX-10.2

8-K